Cell Culture and iPS Core

细胞培养和 iPS 核心

基本信息

批准号：
9762896
负责人：
EDWARD E MORRISEY
金额：
$ 14.95万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-07-01 至 2022-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9762896
关键词：
3-Dimensional Advocate Biological CRISPR/Cas technology Cell Culture Techniques Cell Line Cells Collaborations Core Facility Development Developmental Biology Digestive System Disorders Dimensions Disease Ductal Epithelial Cell Endothelial Cells Ensure Epithelial Cells Esophageal Feedback Fibroblasts Fostering Future Gene Expression Gene-Modified Grant Hepatocyte Human Human Resources Infrastructure Institutes Instruction Intestines Leadership Liver Liver diseases Maintenance Measures Mission Molecular Mus Mycoplasma Infections Names National Institute of Diabetes and Digestive and Kidney Diseases Nature Organoids Pancreas Pennsylvania Process Protocols documentation Quality Control RNA Interference Regenerative Medicine Reproducibility Research Services Standardization Structure of thyroid parafollicular cell System Techniques Technology Time Tissues Universities Viral Vector Vision bile duct cancer cell cost effective cost effectiveness embryonic stem cell established cell line experimental study in vivo induced pluripotent stem cell member programs ranpirnase repository service member stem cell technology stem-like cell three dimensional cell culture tool translational medicine

项目摘要

PROJECT SUMMARY (CELL CULTURE AND iPS CORE) The Cell Culture and iPS Core (CCiC) facility is unique on the University of Pennsylvania campus and in the region. It serves a tremendous need by Center of Molecular Studies in Digestive and Liver Diseases (abbreviated as CMSDLD, which is the NIDDK P30 Digestive Diseases Research Core Center) members for services and technologies underlying Specific Aims related to primary cells and established cell lines, 3D culture systems (organotypic culture and organoids), manipulating gene expression in cell lines through RNA interference and CRISPR/Cas9, and the application of induced pluripotent stem cells (iPS) that have been genetically reprogrammed to an embryonic stem cell-like condition and differentiating such cells to discrete lineages (GI, pancreas, liver). Furthermore, the CCiC provides a rich repository of c cell lines (2D and 3D) that are well annotated for identity, passage and free of Mycoplasma infection thereby providing quality control, rigor and reproducibility. The CCiC provides standardized protocols and regular orientation and instruction, which prove to be cost-effective measures. There are emerging projects related to the use of iPS technology to correct disease states in enteroids and hepatocytes, remarkable illustrations of translational medicine fueled by the CCiC. Through its services, technologies, quality control and time/cost-effectiveness, the CCiC advances the CMSDLD's vision and missions on behalf of members/associate members/personnel.

项目摘要（细胞培养和 iPS 核心）细胞培养和 iPS 核心 (CCiC) 设施在宾夕法尼亚大学校园和美国独一无二地区。它满足了消化和肝脏疾病分子研究中心的巨大需求（简称CMSDLD，即NIDDK P30消化疾病研究核心中心）成员与原代细胞和已建立的细胞系相关的特定目标的服务和技术，3D 培养系统（器官型培养和类器官），通过 RNA 操纵细胞系中的基因表达干扰和CRISPR/Cas9，以及诱导多能干细胞（iPS）的应用通过基因重编程形成胚胎干细胞样状态，并将这些细胞分化为离散的细胞谱系（胃肠道、胰腺、肝脏）。此外，CCiC 提供丰富的 c 细胞系存储库（2D 和 3D），对身份、传代进行了很好的注释，并且没有支原体感染，从而提供质量控制，严谨性和可重复性。 CCiC 提供标准化协议以及定期指导和指导，事实证明这是具有成本效益的措施。有一些新兴项目与使用 iPS 技术相关纠正肠类和肝细胞的疾病状态，这是转化医学的杰出例证 CCiC。通过其服务、技术、质量控制和时间/成本效益，CCiC 不断进步 CMSDLD 代表会员/准会员/人员的愿景和使命。